SYS-CON MEDIA Authors: Mat Mathews, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

Versartis Selects Comprehend Systems

Biopharmaceutical company Versartis, Inc. has selected Comprehend Systems to help facilitate compilation of real-time study information and subject data. The market’s only cloud-based platform with the ability to easily access and analyze data from any clinical IT system, Comprehend Clinical enables all users, including clinical operations and medical affairs, to have immediate access to critical site data for optimal trial management and safety review.

Versartis is developing VRS-317, a novel, long-acting form of recombinant human growth hormone for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and therefore treatment outcomes. The company is currently completing a Phase II clinical trial of VRS-317 in children with GHD.

Versartis selected Comprehend for its ability to provide real-time access to the data in its studies and to simplify what had been a time-consuming process managing multiple data sources. With Comprehend, the company’s clinical operations team has a complete view of every study and access to study information real-time via intuitive dashboards. And once created, those dashboards can be re-used and updated automatically.

“Comprehend connects to all of our clinical trial data, enabling us to view and summarize study progress easily, with little time and effort,” said Eric Humphriss, vice president, clinical operations of Versartis. “Comprehend Clinical was up and running and fully deployed in just three months, which met our already high expectations. The level of expertise across their entire professional services team is excellent.”

“We understand the burdens facing today’s biotech and pharmaceutical companies, and founded Comprehend with companies like Versartis in mind – companies committed to bringing innovative new therapies to market as quickly as possible,” said Rick Morrison, CEO and co-founder of Comprehend. “By removing the inherent barriers that come with multiple data systems and sources, we enable a better and faster clinical research process, and allow Versartis to run the most efficient clinical trials possible, while staying focused on patient care and treatments.

About Versartis, Inc.

Versartis, Inc. (http://ir.versartis.com/) is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and therefore treatment outcomes. The company is currently completing a Phase 2a clinical trial of VRS-317 in children with GHD.

About Comprehend Systems, Inc.

Comprehend Systems, Inc. (www.comprehend.com) offers cloud-based clinical data insights tools that improve the way clinical researchers access, understand, explore and analyze data. Designed specifically for life sciences, Comprehend Clinical ™ enables data managers, monitors and clinical operations executives to identify broad operational and clinical trends across trials and also easily drill down and report on a wide range of factors, including safety issues, regulatory requirements and opportunities for critical time and cost savings. Comprehend Systems was founded in 2010 in Palo Alto by a team of entrepreneurs with decades of combined experience in clinical research and software development.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.